The Phase I study is a randomized, multicenter, double-blind, placebo-controlled study consisting of 3 sequential cohorts to determine the safety and tolerability of AV-1959D at three doses compared to a placebo in patients with early AD.
Phase 1 clinical trial of AV-1959 amyloid-β vaccine for Alzheimer's disease (AD).